These results would have been difficult to obtain using other methods and are of interest in developing a general understanding of why cancer-associated IDH1 and IDH2 variants preferentially catalyze the neomorphic 2OG reduction reaction over the wild-type isocitrate oxidation reaction in cells. The gene discussed is IDH1; the disease is cancer.